"The use of a handheld blood creatinine monitoring system with eGFR calculation provides a good estimation of GFR and allow to identify patients at high risk of acute kidney injury."

"POC measurement of creatinine with eGFR estimation changed the prescription of NSAIDs in almost 25% of patients with previously unknown renal function."

"The results of our study suggest that the limiting characteristics of the StatSensor device are not only bias, but also imprecision. The level of imprecision observed may influence clinical decision-making and limit the usefulness of StatSensor as a CKD screening tool. If choosing to utilize it for either screening for or monitoring CKD, it is essential that clinicians understand the limitations of point-of-care devices and apply this knowledge to test interpretation."

"The POC device tested was not able to reliably assess impairment of renal function in our patient cohort undergoing CESM. Consequently, we still consider classic clinical laboratory testing preferable in patients at potential risk for developing CIN."

The StatSensor-i point-of-care analyzer is a reliable tool for identifying patients at risk of contrast-induced nephropathy. Applying an offset correction significantly improves its diagnostic accuracy and minimizes overdiagnosis, confirming its suitability for efficient, real-time renal function screening directly in the radiology suite.

"Point-of-care clinical chemistry testing was feasible, practical, and well received by staff, and was considered to have a useful role to play in the clinical care of sick obstetric patients at this referral centre."

The study demonstrates that point-of-care (POC) devices like the iSTAT are effective for field-based health surveillance in resource-limited settings, showing high accuracy for creatinine and electrolytes compared to lab standards. While environmental factors like heat and humidity present technical challenges, they can be successfully managed with standardized protocols. Ultimately, reliable POC testing provides a critical, timely alternative to traditional labs, enabling better monitoring of chronic health conditions in vulnerable populations.

"POC testing [i-STAT handheld (Abbott, Princeton, NJ, USA) and the StatSensor Creatinine (Nova Biomedical, Waltham, MA, USA)] can be more accessible in resource-limited settings. The selection of the appropriate device will depend on the use-case."

The POCT devices [Nova StatSensor (creatinine/eGFR); Siemens DCA-Vantage (HbA1C); CityAssays (vitamin-D)] demonstrated acceptable concordance with laboratory-based assays, and patients reported lower levels of discomfort compared to traditional means of blood collection. This study demonstrates the potential of using these devices as acceptable methods for opportunistic testing of "at-risk" individuals within non-traditional community care settings.

POC devices [Nova StatSensor and Abbott iSTAT] are moderately accurate at detecting renal impairment in patients undergoing radiological investigations. They seem to be a good screening tool; however, any low eGFR values should be further examined.

"A three-step testing sequence combining a risk factor questionnaire with a point-of-care test [i-STAT, ABL800 FLEX and StatSensor] and confirmatory laboratory testing appears to be a cost-effective use of NHS resources compared with current practice. The risk of contrast causing acute kidney injury to patients with an estimated glomerular filtration rate of < 30 ml/minute/1.73 m² is uncertain. Cost-effectiveness of point-of-care testing [i-STAT, ABL800 FLEX and StatSensor] appears largely driven by the potential of point-of-care tests to minimise delays within the current computed tomography pathway."

"I-STAT and epoc were, analytically and clinically, the most performant POC devices included in this study but showed to be less user-friendly. StatSensor did not meet any of the error criteria, neither for creatinine nor for eGFR measurements, and gave more clinical major classification errors. However, it proved to be more user-friendly compared to the other POC devices."

"The screening of patients at risk of CI-AKI may be feasible with PoC technology. However, in this study, it was identified that the analyser [Nova StatSensor, Abbott i-STAT and Radiometer ABL800 FLEX] concordance with the laboratory reference varies. It is proposed that further research exploring PoC implementation in imaging department pathways is needed."

The Radiometer ABL800 FLEX showed the best overall concordance with plasma eGFR, though the i-STAT offered higher sensitivity and the StatSensor provided adjustable offset features. Consequently, the optimal device for rapid testing depends on whether a clinical practice prioritizes sensitivity, specificity, or total accuracy when identifying an eGFR below 60 mL/min/1.73 square meters.

The epoc® system is fit for use in surgical and ICU settings, showing high accuracy for blood gases, electrolytes, lactate, and glucose [compared to the RAPIDPoint 500] and for hematocrit/hemoglobin [compared to HemataSTAT-II and Sysmex XN-10]. However, it is not recommended for renal assessment due to a significant positive bias in creatinine [compared to Abbott Architect c8000 and Roche Cobas c702]. This bias leads to inaccurate eGFR calculations and inconsistent CKD staging, requiring laboratory confirmation for clinical decisions.

"POC estimated GFR (eGFR) showed improved performance over laboratory Jaffe eGFR, however POC devices suffered from imprecision and large bias. The laboratory Jaffe method performed poorly, highlighting the need for laboratories to move to enzymatic methods to measure creatinine."

"Creatinine measured with the POC has an acceptable performance when used with the CKD-EPI equation to estimate GFR. Its ability to detect GFR <60 mL/min/1.73 square meters is not significantly different from the classical Roche assay. StatSensor Creatinine (Nova Biomedical) can be used for GFR screening before contrast media injection."

"The POC device reported similar creatinine values to the laboratory and provided significantly faster results. POC creatinine testing is a promising development for trauma practice in austere environments and workup of a subset of stable patients with trauma. Further study is warranted to determine clinical impact, both in hospital-based trauma and austere environments."

"Our results demonstrated that the device provides reliable creatinine measurement and could be used in point-of-care testing. Use of this device in diabetic patients with high glucose level of > or = 200 mg/dL is not recommended"

"These data suggest that whole-blood POC creatinine measurements should be used with caution. Negative interferences observed with these measurements could erroneously suggest adequate renal function near the decision threshold, particularly if estimated glomerular filtration rate is determined. Disparity between whole-blood and plasma matrices partially explains the discordance between whole-blood and plasma creatinine methods."

"Isotope dilution mass spectrometry alignment of the StatSensor will identify most patients with estimated glomerular filtration rate <60 mL/min, but there will be many falsely low estimated glomerular filtration rate results that require laboratory validation. Creatinine results need improvement."

"The creatinine meter provides reliable measurement across a clinically relevant range and has potential use in point-of-care testing."

"A testing sequence combining a risk factor questionnaire, POC test and confirmatory laboratory testing appears to be cost-effective compared to current practice. The cost-effectiveness of POC testing appears to be driven by reduced delays within the CECT pathway. The contribution of intravenous contrast media to acute kidney injury, and the benefits and harms of intravenous hydration remain uncertain."

"A three-step testing sequence combining a risk factor questionnaire with a point-of-care test [i-STAT, ABL800 FLEX and StatSensor] and confirmatory laboratory testing appears to be a cost-effective use of NHS resources compared with current practice. The risk of contrast causing acute kidney injury to patients with an estimated glomerular filtration rate of < 30 ml/minute/1.73 m² is uncertain. Cost-effectiveness of point-of-care testing [i-STAT, ABL800 FLEX and StatSensor] appears largely driven by the potential of point-of-care tests to minimise delays within the current computed tomography pathway."